Hematology
Blood & lymphatic clinical trials
Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We’re tracking 5,088 recruiting studies in this area right now.
By phase
- Not applicable2,108
- Phase 21,119
- Phase 1824
- Phase 1/Phase 2483
- Phase 3350
- Phase 4126
- Phase 2/Phase 378
Top conditions
- Multiple Myeloma334
- Acute Myeloid Leukemia291
- Lymphoma183
- Sickle Cell Disease142
- Myelodysplastic Syndromes129
- Acute Lymphoblastic Leukemia123
- Chronic Lymphocytic Leukemia100
- Leukemia100
- Follicular Lymphoma74
- Hematologic Malignancy68
- Myelodysplastic Syndrome68
- Hodgkin Lymphoma67
- Anemia62
- Mantle Cell Lymphoma62
- Diffuse Large B Cell Lymphoma57
- Lymphedema49
- Non-Hodgkin Lymphoma49
- Small Lymphocytic Lymphoma49
Leading sponsors
- Institute of Hematology & Blood Diseases Hospital, China148
- M.D. Anderson Cancer Center147
- National Cancer Institute (NCI)96
- The First Affiliated Hospital of Soochow University68
- Memorial Sloan Kettering Cancer Center65
- Mayo Clinic61
- City of Hope Medical Center59
- Assistance Publique - Hôpitaux de Paris46
- St. Jude Children's Research Hospital43
- Peking University People's Hospital41
Where studies are running
- California406
- Texas186
- Maryland149
- Alabama147
- Arizona123
- Florida110
- Massachusetts101
- New York98
- Ohio71
- Minnesota68
Recruiting studies5,088 total
- NCT04973605RecruitingPhase 1/Phase 2
Sonrotoclax with steroid and other drugs for multiple myeloma
This early-phase study tests sonrotoclax (a cancer medicine) in people with multiple myeloma that has come back or not responded to prior treatment. It also studies different combinations with dexamethasone plus other standard medicines, aiming to shrink tumors and improve control of the disease.
Birmingham, AlabamaAges 18 years+ - NCT07220616RecruitingPhase 1/Phase 2
DS3790a for people with blood cancers
This trial tests a new drug called DS3790a for people with certain blood cancers that have not responded well to other treatments. The drug is given for the first time in humans, so researchers are checking its safety and how well it works.
New York, New YorkAges 18 years+ - NCT03460977RecruitingPhase 1
Mevrometostat trial for hormone-resistant prostate cancer
This Phase 1 study tests mevrometostat (PF 06821497) in people with castration-resistant prostate cancer to see if it’s safe and how the body responds to it. It may be an option if your cancer is no longer controlled by hormone therapy and your organ health tests are within limits.
Tucson, ArizonaAges 18 years+ - NCT06898983RecruitingPhase 2
Romiplostim for low platelets from leukemia treatment
This trial tests a drug called Romiplostim to help raise low platelet counts caused by leukemia treatment. It is for adults with leukemia whose platelets are below 50 and who may benefit from this therapy.
Hefei, AnhuiAges 18–75 - NCT06087653RecruitingPhase 1/Phase 2
Continuous lenalidomide shot for multiple myeloma
This trial tests a new way to give lenalidomide (Revlimid) as a continuous shot under the skin (subcutaneous infusion) for people with multiple myeloma that has come back or not responded after at least one prior treatment. The goal is to see if this method works better and is easier to tolerate than the standard pill form.
Wilson, North CarolinaAges 18 years+ - NCT06294691RecruitingPhase 3
Timing of stem cell infusion to prevent GVHD in blood cancer
This study is testing whether the timing of a stem cell infusion affects the chance of developing graft-versus-host disease (aGVHD), a common complication after transplant. It may help make transplants safer for people with blood cancers.
Hefei, AnhuiAges 12–60 - NCT07775508RecruitingPhase 1
Car t cell therapy for relapsed or refractory b cell lymphoma
This trial tests a new treatment using your own immune cells, called CAR T cells, that are specially made to find and attack cancer cells in B-cell lymphoma. It may help if your lymphoma has come back or has not gone away after other treatments.
BeijingAges 18–75 - NCT07777406Recruiting
Real-world study of donor stem cell transplant for relapsed/refractory myeloma
This study looks at real-world outcomes in patients who have had a donor stem cell transplant for multiple myeloma that has come back or not responded to treatment. It aims to gather info on how well this approach works in everyday practice.
Chieti, CHAges 18 years+ - NCT06645093Recruiting
Intermittent fasting during chemo for lymphoma
This study tests whether intermittent fasting is safe and doable for people with lymphoma who are getting standard chemotherapy (R-CHOP or ABVD). It aims to see if adding fasting periods can help reduce side effects.
Oslo, OsloAges 18–80 - NCT06587100Recruiting
Activity tracker to prevent hospital stays during cancer treatment
This study tests whether using a wearable activity tracker can help reduce hospitalizations in people undergoing radiation therapy for cancer. Participants will wear a tracker to monitor their activity levels during treatment.
San Francisco, CaliforniaAges 18 years+ - NCT04910568RecruitingPhase 1
Study of cevostamab for people with returning or hard-to-treat myeloma
This trial tests a new drug called cevostamab for people whose multiple myeloma has come back or stopped responding to treatment. It aims to see if the drug is safe and how well it works.
Duarte, CaliforniaAges 18 years+ - NCT07776444Recruiting
Measuring brain blood flow with light and MRI
This study uses a special light-based device and MRI to measure how blood vessels in the brain respond to changes. It may help researchers better understand blood flow in people with and without sickle cell disease.
St Louis, MissouriAges 6–70 - NCT07780240Recruiting
Understanding arm band pain after breast cancer surgery
This study looks at how common axillary web syndrome (a rope-like band in the armpit after breast cancer surgery) is, who gets it, and how it affects arm function. It aims to help doctors better predict and manage this condition.
Istanbul, BAGCILARAges 18–80 - NCT07778212Recruiting
New drug combo for aggressive lymphoma
This trial tests a new combination of drugs for people newly diagnosed with an aggressive type of lymphoma called diffuse large B-cell lymphoma (DLBCL). The combo includes orelabrutinib plus standard chemo-immunotherapy, and may help improve outcomes for those at intermediate or high risk.
Xiamen, FujianAges 18 years+ - NCT07779018RecruitingPhase 2
CAR-T cell therapy after second-line treatment for aggressive B-cell lymphoma
This trial tests a type of immunotherapy called CAR-T cell therapy, which uses your own immune cells to fight lymphoma. It is for people who have already responded well to a second round of chemotherapy and are at high risk of the cancer coming back. The goal is to see if this treatment can keep the cancer away longer.
BeijingAges 18–85 - NCT07594535RecruitingPhase 4
Testing a Blood Pressure Medicine for High Red Blood Cell Count
This study tests whether lisinopril, a common blood pressure medication, can help lower red blood cell counts in people who have elevated hemoglobin levels. Researchers want to see if this drug could offer a simpler treatment option for this condition.
Rochester, MinnesotaAges 18–80 - NCT07779772Recruiting
Diet changes for children with eosinophilic gut disorders
This trial compares different elimination diets to see which one best reduces inflammation in children with eosinophilic gastrointestinal disorders. Your child might have fewer symptoms and a better outcome if the right diet is found.
Adana, SarıcamAges 2–18 - NCT06634589RecruitingPhase 1/Phase 2
Combination therapy for relapsed B-cell blood cancers
This study tests new drug combinations for people with B-cell blood cancers (like lymphoma or leukemia) that have come back or stopped responding to treatment. It aims to see if these combos are safe and can help fight the cancer.
Phoenix, ArizonaAges 18 years+ - NCT06761560RecruitingPhase 2/Phase 3
Hydroxyurea dosing for children with sickle cell anemia
This study looks at whether adjusting the dose of hydroxyurea based on drug levels in the blood works better than the standard approach for treating sickle cell disease in children. It aims to reduce side effects and improve treatment outcomes.
Montreal, QuebecAges 6 months–18 years - NCT07162038RecruitingPhase 1
CAR-T cells plus half-matched stem cell transplant for high-risk blood cancer
This trial tests giving special immune cells (CAR-T cells) that target a protein called CD19 on cancer cells, followed by a half-matched stem cell transplant, to treat high-risk blood cancers. The treatment aims to improve outcomes by using the CAR-T cells to reduce disease before the transplant.
Bethesda, MarylandAges 18–75 - NCT07780097Recruiting
Starting opioid addiction medication after a hospital stay
This study helps people who are in the hospital for opioid use disorder start a medication like methadone or buprenorphine after they leave the hospital. It aims to make starting treatment easier and improve recovery.
Cincinnati, OhioAges 18 years+ - NCT07040189Recruiting
AI nutritional plan for taste changes from chemo
This study tests an AI-created diet plan to help with taste problems caused by chemotherapy. It may help manage taste issues by suggesting recipes tailored to you.
Munich, BavariaAges 18 years+ - NCT06499285RecruitingPhase 3
Study of elritercept for anemia in low-risk MDS needing transfusions
This trial tests an investigational drug called elritercept for adults with a specific type of low-risk MDS (myelodysplastic syndromes) who have anemia (low red blood cells) and need regular blood transfusions. The goal is to see if elritercept can reduce or eliminate the need for transfusions.
Duarte, CaliforniaAges 18 years+ - NCT07218341RecruitingPhase 4
Continuing pirtobrutinib for CLL or SLL patients
This trial continues treatment with the drug pirtobrutinib for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who are already in another study. It is not open to new patients.
Mobile, AlabamaAges 18 years+
Common questions
- How many blood & lymphatic clinical trials are recruiting?
- Clin2 is tracking 5,088 recruiting hematology studies from the U.S. registry right now, out of 7,677 we cover in this area in total.
- What does “Blood & lymphatic” cover here?
- Anemia, clotting disorders, and other conditions of the blood and lymphatic system. We group each study into blood & lymphatic based on the conditions it studies, so you can scan the whole therapeutic area at once and drill into a specific condition.
- How do I find a blood & lymphatic trial near me?
- Use the search to filter blood & lymphatic studies by location and eligibility. Every Clin2 trial page explains the criteria in plain English and offers a short, optional pre-screen for a fit read — the study team makes the final decision.
Other specialties
- Cancer
- Brain & nervous system
- Heart & circulation
- Hormones & metabolism
- Mental health
- Digestive system
- Lungs & breathing
- Immune system & allergy
- Women’s health & pregnancy
- Skin
- Kidney & urinary
- Infections
- Genetic & congenital
- Bones, joints & muscles
- Pain
- Injuries & trauma
- Mouth & dental
- Eyes & vision
- Ear, nose & throat
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov; specialty groupings are derived from each study’s conditions. Talk with your doctor about whether a specific trial is right for you.